Primary ciliary dyskinesia: tackling the underlying cause of this debilitating, rare condition
Published on 6 May 2015
Children with a debilitating, inherited illness called primary ciliary dyskinesia (PCD) may one day benefit from research by Professor Chris O’Callaghan and colleagues, of University College London and Great Ormond Street Hospital. Children with this rare condition have a persistent cough from birth and face a lifetime of recurrent chest infections. They often develop hearing loss and eventually permanent lung damage. Treatment with antibiotics and daily physiotherapy to clear mucus from the lungs helps, but there’s no cure. Professor O’Callaghan is investigating a possible new approach to treatment, in the hope of tackling the cause of children’s symptoms and improving their lives.
How are children’s lives affected now?
“Babies and children with PCD have a persistent, wet-sounding cough, which never goes away, and a constantly runny or partially blocked nose,” says Professor O’Callaghan. “Symptoms continue daily and are lifelong.”
“Exercise, coughing and physiotherapy sessions – which children need a number of times a day – help by removing some of the mucus from children’s lungs,” continues Professor O’Callaghan. “Unfortunately, though, many children develop long-term chest infections, which can cause progressive – and permanent – lung damage. Over half of children with PCD also have hearing problems, meaning they need hearing aids.”
Long-term infections require treatment with multiple courses of antibiotics, with children sometimes needing to stay in hospital. Very badly affected children may eventually require lung transplantation.
“Records from clinics in the UK suggest around 90 children are diagnosed with PCD here each year,” says Professor O’Callaghan.1 “Worryingly there’s a lack of evidence on the best way to treat them and no cure.” Research into better treatment is needed urgently.
How could this research help?
The team’s ultimate goal is to develop a new treatment for PCD that corrects the underlying cause of children’s symptoms – faults in tiny hair-like structures called cilia that line the surface of the airways.
“We believe four out of every 10 children with PCD in the UK have what we call a nonsense mutation in their DNA,” says Professor O’Callaghan.2 These mutations, or changes, stop children’s cilia from working normally – the cilia don’t sweep mucus or infectious agents, such as bacteria, out of the lungs properly.
“Evidence suggests a number of drugs can help overcome problems caused by nonsense mutations,” continues Professor O’Callaghan. “We’re studying two of these drugs in the laboratory to see if they can correct defects in cilia on cells taken from children with PCD. This will require a lot of research.”
“If the drugs we’re testing show promise in the laboratory, clinical trials could follow quickly in children with PCD, because there’s already good evidence to support their safety in humans,” says Professor O’Callaghan. “Drugs that can restore the ability of cilia to work properly could help children move mucus out of their lungs, which would hopefully improve their health.”
1. Personal communication with Professor O’Callaghan, based on audit figures from PCD national diagnostic service.
2. Personal communication between Professor O’Callaghan and Dr Hannah Mitchison of University College London’s Institute of Child Health.
|Project Leader||Professor Chris L O'Callaghan BMedSci FRCPCH, FRCP, FSB, DM, PhD|
|Location||Respiratory, Critical Care & Anasesthesia, Institute of Child Health, University College London, and Great Ormond Street Hospital|
|Grant awarded||21 November 2014|
|Start date||1 March 2015|
|End date||1 September 2018|
|Acknowledgements||This project is supported by a generous grant from The Henry Smith Charity|
We do not provide medical advice. If you would like more information about a condition or would like to talk to someone about your health, contact NHS Choices or speak to your GP. Please see our useful links page for some links to health information, organisations we are working with and other useful organisations. We hope you will find these useful. We are not responsible for the content of any of these sites.